Helixmith is a late-stage clinical development company conducting several phase 2 and phase 3 clinical trials, primarily in the US. The company is listed on Korea’s stock market, the KOSDAQ (084990).
Helixmith has several disease programs at various clinical stages, from phase 1 to phase 3: gene therapy for diabetic complications (DPN, DFU), gene therapy for lower limb disorder (claudication, DFU, CLI), and an ALS-focused program.
All are based on a scientific platform capitalizing on HGF/c-Met signaling, and three modalities have been developed to maximize this clinically important signaling pathway.
Helixmith has an ALS-focused program called DART (Defeating ALS through Regenerative Therapeutics), in which a multi-modal parallel approach is taken, involving three different drug candidates.
Helixmith is also will discuss their other programs in diabetic complications, lower limb disorder, or neuromuscular diseases.
Helixmith has several disease programs at various clinical stages, from phase 1 to phase 3: gene therapy for diabetic complications (DPN, DFU), gene therapy for lower limb disorder (claudication, DFU, CLI), and an ALS-focused program.
All are based on a scientific platform capitalizing on HGF/c-Met signaling, and three modalities have been developed to maximize this clinically important signaling pathway.
Helixmith has an ALS-focused program called DART (Defeating ALS through Regenerative Therapeutics), in which a multi-modal parallel approach is taken, involving three different drug candidates.
Helixmith is also will discuss their other programs in diabetic complications, lower limb disorder, or neuromuscular diseases.
Ticker:
084990
Exchange:
KOSDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
Not Provided
Main Therapeutic Focus:
CNS/Neurological
Lead Product in Development:
Engensis
Development Phase of Primary Product:
Phase III
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
